Avanza Fonder AB Takes Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Avanza Fonder AB acquired a new position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 16,652 shares of the biopharmaceutical company’s stock, valued at approximately $157,000.

Other hedge funds also recently made changes to their positions in the company. Park Avenue Securities LLC bought a new stake in shares of Amicus Therapeutics during the fourth quarter worth $123,000. Diversified Trust Co boosted its holdings in Amicus Therapeutics by 9.7% in the fourth quarter. Diversified Trust Co now owns 81,758 shares of the biopharmaceutical company’s stock valued at $770,000 after acquiring an additional 7,257 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Amicus Therapeutics during the third quarter worth $107,000. Old West Investment Management LLC raised its position in shares of Amicus Therapeutics by 617.2% in the 3rd quarter. Old West Investment Management LLC now owns 340,441 shares of the biopharmaceutical company’s stock worth $3,636,000 after acquiring an additional 292,976 shares in the last quarter. Finally, Neo Ivy Capital Management bought a new stake in Amicus Therapeutics in the third quarter worth approximately $702,000.

Amicus Therapeutics Price Performance

Shares of NASDAQ FOLD opened at $9.41 on Monday. The stock’s 50-day simple moving average is $9.70 and its two-hundred day simple moving average is $10.53. The firm has a market capitalization of $2.81 billion, a P/E ratio of -27.68, a P/E/G ratio of 1.25 and a beta of 0.62. The company has a quick ratio of 2.42, a current ratio of 3.15 and a debt-to-equity ratio of 2.18. Amicus Therapeutics, Inc. has a twelve month low of $8.78 and a twelve month high of $14.03.

Analyst Upgrades and Downgrades

FOLD has been the topic of several research reports. Guggenheim upped their price objective on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a report on Monday, January 13th. StockNews.com lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. JPMorgan Chase & Co. increased their target price on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, November 12th. Finally, Bank of America lifted their price objective on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, October 17th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $16.88.

Insider Transactions at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $11.46, for a total transaction of $85,950.00. Following the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at $10,161,054.84. This trade represents a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 22,901 shares of company stock valued at $259,863 in the last quarter. Insiders own 2.20% of the company’s stock.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.